Increased frequencies of circulating and tumor-resident Vδ1⁺ T cells in patients with diffuse large B-cell lymphoma

References

• Vantourout P, Hayday A. Six-of-the-best: unique contributions of γδ T cells to immunology. Nat Rev Immunol. 2013;13:88–100.
   PubMed Web of Science ®Google Scholar
• Champagne E. γδ T cell receptor ligands and modes of antigen recognition. Arch Immunol Ther Exp (Warsz). 2011;59:117–137.
   PubMed Web of Science ®Google Scholar
• Thedrez A, Sabourin C, Gertner J, et al. Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue? Immunol Rev. 2007;215:123–135.
   PubMed Web of Science ®Google Scholar
• Wang H, Henry O, Distefano MD, et al. Butyrophilin 3A1 plays an essential role in prenyl pyrophosphate stimulation of human Vγ2Vδ2 T cells. J Immunol (Baltim Md 1950). 2013;191:1029–1042.
   PubMed Web of Science ®Google Scholar
• Nedellec S, Sabourin C, Bonneville M, et al. NKG2D costimulates human V gamma 9V delta 2 T cell antitumor cytotoxicity through protein kinase C theta-dependent modulation of early TCR-induced calcium and transduction signals. J Immunol (Baltim Md 1950). 2010;185:55–63.
   PubMed Web of Science ®Google Scholar
• Choudhary A, Davodeau F, Moreau A, et al. Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma. J Immunol (Baltim Md 1950). 1995;154:3932–3940.
   PubMed Web of Science ®Google Scholar
• Ferrarini M, Heltai S, Pupa SM, et al. Killing of laminin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing gammadelta(+) t-cell receptors. J Natl Cancer Inst. 1996;88:436–441.
   PubMed Web of Science ®Google Scholar
• Groh V, Rhinehart R, Secrist H, et al. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA. 1999;96:6879–6884.
   PubMed Web of Science ®Google Scholar
• Malkovska V, Cigel FK, Armstrong N, et al. Antilymphoma activity of human gamma delta T-cells in mice with severe combined immune deficiency. Cancer Res. 1992;52:5610–5616.
   PubMed Web of Science ®Google Scholar
• Malkovska V, Cigel F, Storer BE. Human T cells in hu-PBL-SCID mice proliferate in response to Daudi lymphoma and confer anti-tumour immunity. Clin Exp Immunol. 1994;96:158–165.
   PubMed Web of Science ®Google Scholar
• Peters C, Oberg H-H, Kabelitz D, et al. Phenotype and regulation of immunosuppressive Vδ2-expressing γδ T cells. Cell Mol Life Sci. 2014;71:1943–1960.
   PubMed Web of Science ®Google Scholar
• Peng G, Wang HY, Peng W, et al. Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity. 2007;27:334–348.
   PubMed Web of Science ®Google Scholar
• Ma C, Zhang Q, Ye J, et al. Tumor-infiltrating γδ T lymphocytes predict clinical outcome in human breast cancer. J Immunol (Baltim Md 1950). 2012;189:5029–5036.
   PubMed Web of Science ®Google Scholar
• Wu P, Wu D, Ni C, et al. γδT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity. 2014;40:785–800.
   PubMed Web of Science ®Google Scholar
• Dessarthe B, Thedrez A, Latouche, et al. CRTAM receptor engagement by Necl-2 on tumor cells triggers cell death of activated Vγ9Vδ2 T cells. J Immunol (Baltim Md 1950). 2013;190:4868–4876.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms. Blood. 2016;27:2375–2390.
   Web of Science ®Google Scholar
• Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood. 2007;110:29–36.
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282.
   PubMed Web of Science ®Google Scholar
• Keane C, Gill D, Vari F, et al. CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy. Am J Hematol. 2013;88:273–276.
   PubMed Web of Science ®Google Scholar
• Muris JJF, Meijer CJLM, Cillessen SAGM, et al. Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas. Leukemia. 2004;18:589–596.
   PubMed Web of Science ®Google Scholar
• Gibson SE, Swerdlow SH, Felgar RE. Natural killer cell subsets and natural killer-like T-cell populations in benign and neoplastic B-cell proliferations vary based on clinicopathologic features. Hum Pathol. 2011;42:679–687.
   PubMed Web of Science ®Google Scholar
• Silva-Santos B, Serre K, Norell H. γδ T cells in cancer. Nat Rev Immunol. 2015;15:683–691.
   PubMed Web of Science ®Google Scholar
• Poggi A, Venturino C, Catellani S, et al. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res. 2004;64:9172–9179.
   PubMed Web of Science ®Google Scholar
• Cordova A, Toia F, La Mendola C, et al. Characterization of human γδ T lymphocytes infiltrating primary malignant melanomas. PLoS One. 2012;7:e49878.
   PubMed Web of Science ®Google Scholar
• Dieli F, Poccia F, Lipp M, et al. Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. J Exp Med. 2003;198:391–397.
   PubMed Web of Science ®Google Scholar
• Thedrez A, Lavoué V, Dessarthe B, et al. A quantitative deficiency in peripheral blood Vγ9Vδ2 cells is a negative prognostic biomarker in ovarian cancer patients. PLoS One. 2013;8:e63322.
   PubMed Web of Science ®Google Scholar
• Azzaoui I, Uhel F, Rossille D, et al. T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells. Blood. 2016;128:1081–1092.
   PubMed Web of Science ®Google Scholar
• Kryczek I, Banerjee M, Cheng P, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009;114:1141–1149.
   PubMed Web of Science ®Google Scholar
• Martin-Orozco N, Muranski P, Chung Y, et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 2009;31:787–798.
   PubMed Web of Science ®Google Scholar
• Rei M, Gonçalves-Sousa N, Lança T, et al. Murine CD27(–) Vγ6(+) γδ T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages. Proc Natl Acad Sci USA. 2014;111:E3562–E3570.
   PubMed Web of Science ®Google Scholar
• Yang Z-Z, Novak AJ, Ziesmer SC, et al. Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res. 2009;69:5522–5530.
   PubMed Web of Science ®Google Scholar
• Boles KS, Barchet W, Diacovo T, et al. The tumor suppressor TSLC1/NECL-2 triggers NK-cell and CD8+ T-cell responses through the cell-surface receptor CRTAM. Blood. 2005;106:779–786.
   PubMed Web of Science ®Google Scholar
• Pike BL, Greiner TC, Wang X, et al. DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status. Leukemia. 2008;22:1035–1043.
   PubMed Web of Science ®Google Scholar